DCCR

DRUG5 trials

Sponsors

Essentialis, Inc., Soleno Therapeutics, Inc.

Conditions

Prader-Willi Syndrome

Phase 1

Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

CompletedNCT02034071

Essentialis, Inc.Prader-Willi Syndrome

Start: 2014-04-30End: 2015-05-31Updated: 2016-09-01

Phase 3

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

CompletedNCT03440814

Soleno Therapeutics, Inc.Prader-Willi Syndrome

Start: 2018-05-09End: 2020-05-01Updated: 2023-09-21

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

CompletedNCT03714373

Soleno Therapeutics, Inc.Prader-Willi Syndrome

Start: 2018-10-01End: 2023-08-17Updated: 2024-04-19

An Open-Label Study of DCCR Tablet in Patients With PWS

WithdrawnNCT04086810

Soleno Therapeutics, Inc.Prader-Willi Syndrome

Start: 2019-10-31End: 2019-10-31Updated: 2021-08-03

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Active, not recruitingNCT05701774

Soleno Therapeutics, Inc.Prader-Willi Syndrome

Start: 2023-01-31End: 2028-06-30Target: 83Updated: 2025-04-02

Related Papers

Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study

Journal of Neurodevelopmental Disorders2024-04-265 citations